ストックスクリーナーアプリを入手
509.04
0.53%
-2.70
アフターアワーズ：
512.10
3.06
+0.60%
前日終値:
$511.74
開ける：
$511.78
24時間の取引高:
861.63K
Relative Volume:
0.55
時価総額：
$131.41B
収益：
$11.02B
当期純損益:
$-535.60M
株価収益率:
-231.38
EPS:
-2.2
ネットキャッシュフロー:
$-978.00M
1週間 パフォーマンス:
-0.62%
1か月 パフォーマンス:
+5.97%
6か月 パフォーマンス:
+10.24%
1年 パフォーマンス:
+22.36%
1日の値動き範囲:
$503.99
$512.71
1週間の範囲:
$501.00
$515.67
52週間の値動き範囲:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
VRTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
509.04 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.14 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.52 | 36.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
280.96 | 36.37B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.47 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges - Investing.com
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $512 From $500, Keeps Overweight Rating - Marketscreener.com
Jim Cramer on Vertex (VRTX): “A Revolutionary Anti-Pain Drug” - Insider Monkey
Jim Cramer on Vertex (VRTX): "A Revolutionary Anti-Pain Drug" - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Nasdaq
Insider Sell: David Altshuler Sells Shares of Vertex Pharmaceuti - GuruFocus.com
Insider Sell: David Altshuler Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus.com
Should You Buy Vertex Pharmaceuticals Stock At $510? - Trefis
Vertex Pharmaceuticals (VRTX) Rises But Trails Market: What Investors Should Know - Yahoo Finance
Cystic Fibrosis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Is Vertex Pharmaceuticals (VRTX) the Best Diabetes Stock to Buy According to Billionaires? - Insider Monkey
Global mRNA-based Vaccines and Therapeutics Market is expected to Grow at a decent CAGR during the Study Period (2019-2032) | DelveInsight - The Globe and Mail
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack - Yahoo Finance
Ed Kaye, founding CEO of Stoke Therapeutics, steps down - The Business Journals
Vertex Pharmaceuticals (VRTX): One of the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Vertex's Pain Drug: Big Pharma's Next Major Success? - MSN
Is Vertex Pharmaceuticals (VRTX) Among the Best High Growth Stocks? - Insider Monkey
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
DA Davidson maintains Buy on Vertex shares, target $34 By Investing.com - Investing.com UK
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation - The Motley Fool
13 High Growth Large Cap Stocks To Invest In - Insider Monkey
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain - Business Wire
Layoff Tracker: GRO Biosciences Cuts Staff Amid Quest for Strategic Alternatives - BioSpace
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today - Yahoo Finance
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Benzinga
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics - Benzinga
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by StockNews.com - Defense World
Vertex Pharmaceuticals EVP sells $1.6 million in stock By Investing.com - Investing.com Australia
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals EVP sells $1.62 million in stock - Investing.com India
Vertex Pharmaceuticals EVP sells $1.6 million in stock - Investing.com
Vertex Pharmaceuticals Executives Sell Shares - TradingView
Vertex Pharmaceuticals CFO sells shares worth $1.65 million - Investing.com
Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds - Insider Monkey
Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio? - MSN
Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report? - Yahoo Finance
Where Will Vertex Pharmaceuticals Be in 10 Years? - sharewise
Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA - PMLiVE
3 Reasons to Avoid VRTX and 1 Stock to Buy Instead - Yahoo Finance
Rep. Jefferson Shreve Purchases Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
Vertex at Leerink: Strategic Moves and Growth Prospects - Investing.com
UK MHRA approves Vertex’s Alyftrek for cystic fibrosis - Pharmaceutical Business Review
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Jones Financial Companies Lllp - Defense World
UnitedHealth slots Vertex's non-opioid pain med at top of tiered formulary - FirstWord Pharma
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies - Benzinga
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment - Yahoo Finance
Vertex Pharmaceuticals Says Journavx Non-Opioid Pain Killer Added to Optum Formulary - Marketscreener.com
Vertex Announces UK Mhra Approval Of Alyftrek -March 07, 2025 at 11:32 am EST - Marketscreener.com
Vertex Pharmaceuticals Gets UK Regulatory Approval for Alyftrek to Treat Cystic Fibrosis - Marketscreener.com
(Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
4.06%
大文字化:
|
ボリューム (24 時間):